Previous 10 | Next 10 |
Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...
Shares of Avalon GloboCare Corp. (NASDAQ:AVCO) traded at a new 52-week low today of $0.97. So far today approximately 348,000 shares have been exchanged, as compared to an average 30-day volume of 392,000 shares. Avalon Globocare Corp is an intelligent biotech developer and healthcare se...
Avalon GloboCare Corp. (NASDAQ:AVCO) traded today at a new 52-week low of $0.95. So far today approximately 348,000 shares have been exchanged, as compared to an average 30-day volume of 392,000 shares. Avalon GloboCare Corp. (NASDAQ:AVCO) has potential upside of 8.3% based on a current ...
Avalon GloboCare Corp. (NASDAQ:AVCO) traded at a new 52-week low today of $1.01. Approximately 348,000 shares have changed hands today, as compared to an average 30-day volume of 392,000 shares. Avalon GloboCare Corp. share prices have moved between a 52-week high of $2.19 and the curren...
Shares of Avalon GloboCare Corp. (NASDAQ:AVCO) traded at a new 52-week low today of $0.98. So far today approximately 348,000 shares have been exchanged, as compared to an average 30-day volume of 392,000 shares. Avalon GloboCare Corp. (NASDAQ:AVCO) has potential upside of 6.0% based on ...
Avalon GloboCare Corp. (NASDAQ:AVCO) traded at a new 52-week low today of $1.01. Approximately 348,000 shares have changed hands today, as compared to an average 30-day volume of 392,000 shares. Avalon GloboCare Corp. (NASDAQ:AVCO) is currently priced 1.9% above its average consensus ana...
Avalon GloboCare ([[AVCO]] -3.9%) announces that it has entered into a collaboration agreement with the University of Pittsburgh Medical Center ((UPMC)) Hillman Cancer Center to advance the clinical development and production of Avalon’s next-generation, chimeric antigen receptor ...
Development of FLASH-CAR™ RNA-based cellular therapies includes utilization of Avalon’s new Point-of-Care Modular Autonomous Processing System (PMAPsys™ ) First FLASH-CAR™ candidate, AVA-011, on-track for clinical study in B-cell lymphoblastic l...
Dual cutting edge technology approach using CRISPR-based genome editing and QTY code-based truncated chemokine receptors Expansion of co-development program with Dr. Shuguang Zhang at the Massachusetts Institute of Technology (MIT) Media Lab to halt mobilization and spread o...
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. ( Nasdaq: SYTA, SYTAW ) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...